In this episode of Curing with Sound, we speak with Bill Traynor, a Canadian adventurer whose life shifted dramatically when he was diagnosed with ALS (Lou Gehrig’s disease), a neurodegenerative disorder with an average life expectancy of just two to five years. Once enjoying high-impact activities like skydiving, race car driving, and scuba diving, Bill’s active lifestyle came to an abrupt halt.
Determined to face the diagnosis head-on, Bill became the first person to participate in a focused ultrasound clinical trial at Sunnybrook Research Institute, where researchers used a newly developed helmet to noninvasively and temporarily open the blood-brain barrier. This breakthrough allowed direct delivery of immunotherapy to his brain to reduce ALS-related neuroinflammation.
Discussion highlights:
- World-First Medical Breakthrough: Researchers used a new domed helmet, designed to temporarily open the blood-brain barrier in very specific regions of the brain, helping push more medication into areas affected by ALS. This new helmet provides enhanced image guidance, faster treatment times, and targeting capacity for the investigation of personalized therapies for patients with a variety of neurological conditions and diseases of the brain
- Promising Early Results: After treatment, the medication delivered to the brain stays in the tissue for two to eight weeks. Researchers will now track the trial participants over the next five months before deciding whether and how to expand this research.
—————————-
QUESTIONS?
Email [email protected] if you have a question or comment about the show, or if you would you like to connect about future guest appearances.
Email [email protected] if you have questions about focused ultrasound or the Foundation